| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA (NCT04519879) | City of Hope Medical Center | 2021-05-10 |
| 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer (NCT04857502) | Jonsson Comprehensive Cancer Center | 2021-04-27 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer (NCT03902951) | Jonsson Comprehensive Cancer Center | 2021-03-17 |
| Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer (NCT03698370) | Andrei Iagaru | 2020-12-15 |
| Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation (NCT04457232) | Jonsson Comprehensive Cancer Center | 2020-09-09 |
| A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer (NCT04190446) | Mayo Clinic | 2020-01-06 |
| Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer (NCT03796767) | University of Utah | 2019-09-09 |
| Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery (NCT03515577) | Jonsson Comprehensive Cancer Center | 2019-04-12 |
| Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy (NCT03582774) | Jonsson Comprehensive Cancer Center | 2018-07-12 |
| Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial (NCT03371719) | NRG Oncology | 2018-06-20 |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer (NCT02881242) | Jonsson Comprehensive Cancer Center | 2018-01-30 |
| 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment (NCT02673151) | Andrei Iagaru | 2017-05-20 |
| Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer (NCT03016741) | Northwestern University | 2017-03-31 |
| Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation (NCT02899221) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-03-21 |
| Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer (NCT03122743) | Wake Forest University Health Sciences | 2017-02-22 |
| Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer (NCT02935205) | Mamta Parikh | 2017-01-17 |
| Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer (NCT03123978) | University of California, Davis | 2017-01-09 |
| Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer (NCT02807805) | Mamta Parikh | 2016-10-01 |
| Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy (NCT02940262) | Jonsson Comprehensive Cancer Center | 2016-09-15 |
| Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 (NCT02601014) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-03-15 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer (NCT02532114) | University of Washington | 2015-12-31 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (NCT02522715) | OHSU Knight Cancer Institute | 2015-08-13 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer (NCT02499835) | University of Wisconsin, Madison | 2015-07-01 |
| Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy (NCT02420652) | Rutgers, The State University of New Jersey | 2015-06-23 |
| 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer (NCT02488070) | Stanford University | 2015-06-01 |
| Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT02159950) | Roswell Park Cancer Institute | 2015-01-01 |
| Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide (NCT02312557) | OHSU Knight Cancer Institute | 2014-11-18 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer (NCT02206334) | NRG Oncology | 2014-08-01 |
| Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy (NCT02099864) | OHSU Knight Cancer Institute | 2014-02-05 |
| Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer (NCT01787331) | University of California, San Francisco | 2013-10-29 |
| Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T (NCT01833208) | Roswell Park Cancer Institute | 2013-07-03 |
| Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (NCT01953640) | Mayo Clinic | 2013-05-30 |
| Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide (NCT02228265) | OHSU Knight Cancer Institute | 2013-03-12 |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (NCT01786265) | M.D. Anderson Cancer Center | 2013-02-05 |
| Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01503229) | University of Washington | 2012-12-01 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (NCT01576172) | National Cancer Institute (NCI) | 2012-03-30 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer (NCT01251861) | National Cancer Institute (NCI) | 2011-03-17 |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (NCT01120236) | National Cancer Institute (NCI) | 2010-12-01 |
| Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01145508) | National Cancer Institute (NCI) | 2010-08-01 |
| Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel (NCT01253642) | OHSU Knight Cancer Institute | 2010-07-12 |
| Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases (NCT00936975) | National Cancer Institute (NCI) | 2009-09-01 |
| Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer (NCT01050504) | University of Washington | 2009-08-01 |
| Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NCT00486642) | National Cancer Institute (NCI) | 2007-09-01 |
| Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer (NCT00536991) | Roswell Park Cancer Institute | 2006-10-01 |
| A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer (NCT00108732) | National Cancer Institute (NCI) | 2006-02-01 |
| Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer (NCT00170157) | Mayo Clinic | 2004-06-01 |
| Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (NCT00064129) | National Cancer Institute (NCI) | 2003-05-13 |
| F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer (NCT03501940) | Andrei Iagaru | |